- Home
- PSHG vs MIRA Comparison
PSHG vs MIRA Comparison
Compare PSHG & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- MIRA
- Stock Information
- Founded
- PSHG 2010
- MIRA 2020
- Country
- PSHG Greece
- MIRA United States
- Employees
- PSHG N/A
- MIRA N/A
- Industry
- PSHG Marine Transportation
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- MIRA Health Care
- Exchange
- PSHG Nasdaq
- MIRA Nasdaq
- Market Cap
- PSHG 20.1M
- MIRA 20.5M
- IPO Year
- PSHG N/A
- MIRA 2023
- Fundamental
- Price
- PSHG $1.58
- MIRA $0.95
- Analyst Decision
- PSHG Strong Buy
- MIRA Strong Buy
- Analyst Count
- PSHG 1
- MIRA 2
- Target Price
- PSHG $6.50
- MIRA $14.00
- AVG Volume (30 Days)
- PSHG 33.7K
- MIRA 359.3K
- Earning Date
- PSHG 02-20-2025
- MIRA 05-12-2025
- Dividend Yield
- PSHG N/A
- MIRA N/A
- EPS Growth
- PSHG N/A
- MIRA N/A
- EPS
- PSHG 1.11
- MIRA N/A
- Revenue
- PSHG $87,445,000.00
- MIRA N/A
- Revenue This Year
- PSHG N/A
- MIRA N/A
- Revenue Next Year
- PSHG $32.01
- MIRA N/A
- P/E Ratio
- PSHG $1.44
- MIRA N/A
- Revenue Growth
- PSHG N/A
- MIRA N/A
- 52 Week Low
- PSHG $1.48
- MIRA $0.51
- 52 Week High
- PSHG $2.58
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- PSHG 50.41
- MIRA 40.90
- Support Level
- PSHG $1.57
- MIRA $0.98
- Resistance Level
- PSHG $1.68
- MIRA $1.29
- Average True Range (ATR)
- PSHG 0.05
- MIRA 0.12
- MACD
- PSHG 0.01
- MIRA -0.02
- Stochastic Oscillator
- PSHG 49.84
- MIRA 12.89
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.